Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 7/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4671255 | 0.91 | P2RY12 (0.35) | TDP1CYP17A1MEN1KMT2AP2RY12 | |
| SCHEMBL4671250 | 0.91 | P2RY12 (0.35) | TDP1CYP17A1MEN1KMT2AP2RY12 | |
| SCHEMBL4674105 | 0.91 | P2RY12 (0.35) | TDP1CYP17A1MEN1KMT2AP2RY12 | |
| SCHEMBL18516015 | 0.84 | MEN1 (0.34) | TDP1CYP17A1MEN1KMT2ACYP26A1 | |
| SCHEMBL24591255 | 0.83 | HRH4 (0.45) | MEN1KMT2ACYP26A1 | |
| SCHEMBL23067830 | 0.83 | P2RY12 (0.38) | CYP17A1P2RY12 | |
| SCHEMBL19742233 | 0.83 | FOLH1 (0.49) | — | |
| SCHEMBL19742232 | 0.83 | FOLH1 (0.49) | — | |
| SCHEMBL15653973 | 0.83 | CYP17A1 (0.34) | TDP1CYP17A1MEN1KMT2ACYP26A1 | |
| SCHEMBL19742218 | 0.82 | FOLH1 (0.49) | EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070695-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | TBXAS1 3018/4885EGLN3 3294/4885TDP1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.